Asia-Pacific Continuous Glucose Monitoring Market Analysis, Estimates and Forecasts, 2017-2020 and 2021-2030 – ResearchAndMarkets.com
DUBLIN – (COMMERCIAL THREAD) – The report “Asia-Pacific Continuous Glucose Monitoring Market, By Component, By Demographics, By End User, Estimate and Forecast, 2017-2030” has been added to ResearchAndMarkets.com offer.
The Asia-Pacific Continuous Glucose Monitoring (CGM) market held a market value of USD 1,081.6 million in 2021 and is expected to reach USD 2,967.2 million by 2030. The market is expected to grow at a CAGR of 12.22% from 2022 to 2030.
Continuous blood glucose monitors (CGMs) are devices used to monitor blood sugar continuously. The market should be driven by the increased awareness of people on surveillance and preventive health. Besides, the increase in the diabetic population is also expected to fuel the growth of the market.
Despite the driving factors, inaccurate and expensive systems are also expected to hamper the growth of the market. In addition, inadequate repayment facilities are expected to hamper the growth of the market.
Increase in the diabetic population
The increasing prevalence of diabetes is also leading to an increase in the diabetic population which is driving the growth of the market. According to the International Diabetes Federation (IDF), as of November 2019, around 88 million adults in the Southeast Asian region had diabetes. This number has been estimated to be around 153 million by 2045. Hence, the increase in the diabetic population is expected to drive the demand for continuous glucose monitors, thereby fueling the growth of the market.
The sensors segment is estimated to hold the largest market share of around 44% due to increasing technological advancements. The transmitters and receivers segment is expected to represent the second largest market share. They are the most durable component of the CGM device, which contributes to the growth of its market.
The segment of the adult population is expected to hold the largest market share and is also expected to grow at the fastest growth rate of 12.49% over the projected period due to the high incidence rate of diabetes in the adult population compared to to the infant population.
The critical care segment is expected to account for around 45% of the market size of the home healthcare segment in 2021 and this share is expected to reach 41% by 2030. The home healthcare segment is expected to experience significant growth due to the growing adoption of CGM devices in homes.
By country, the Asia Pacific Continuous Glucose Monitoring (CGM) market is divided into China, India, Japan, South Korea, Australia and New Zealand, Indonesia, ASEAN, and the rest of Asia Pacific. ASEAN is further classified into Malaysia, Thailand, Philippines, Vietnam, Singapore, and Indonesia.
The Chinese segment is estimated to hold the largest market share of around 36.2% due to the increasing prevalence of diabetes in China. According to the International Diabetes Federation (IDF), as of November 2019, there were around 114 million cases of diabetes in China.
On the other hand, India is expected to experience the fastest growth rate of 13.35% during the forecast period due to the increasing adoption of technologically advanced products in the country for the management of diabetes and d ‘other chronic diseases.
Major players in the Asia Pacific Continuous Glucose Monitoring (CGM) market are Abbott Laboratories, DexCom, Inc., A. Menarini Diagnostics, Echo Therapeutics, Inc., GlySens Incorporated, Johnson & Johnson, Medtronic plc, Senseonics Holdings , Inc., F Hoffmann-La Roche Ltd, and other major players. The cumulative market share of the nine main players exceeds 78%.
These market players are engaged in mergers and acquisitions, collaborations and new product launches, among other initiatives, to strengthen their presence in the market. For example, in August 2021, Abbott received US FDA approval for the Freestyle Libre 2 iOS app, which is compatible with iPhones. This provided a complete digital offering for its FreeStyle Libre 2 integrated continuous blood glucose monitoring (iCGM) system.
Main topics covered:
Chapter 1. Research framework
1.1 Research objective
1.2 Product overview
1.3 Market segmentation
Chapter 2. Research methodology
2.1 Qualitative research
2.1.1 Primary and secondary sources
2.2 Quantitative research
2.2.1 Primary and secondary sources
2.3 Distribution of the main respondents to the research, by region
2.4 Study hypothesis
2.5 Estimation of the market size
2.6. Data triangulation
Chapter 3. Executive Summary: Asia-Pacific Continuous Glucose Monitoring (CGM) Market
Chapter 4. Asia-Pacific Continuous Glucose Monitoring (CGM) Market Overview
4.1. Industry value chain analysis
4.1.2. Technology integrator
4.1.3. Service provider
4.1.4. Final user
4.2. Industry outlook
4.2.1. Prevalence of diabetes in Asia-Pacific
4.2.2. Asia-Pacific Continuous Blood Glucose Monitoring Sales
4.3. PESTLE analysis
4.4. Porter’s Five Forces Analysis
4.5. Market dynamics and trends
4.6. Assessment of the impact of Covid-19 on the market growth trend
4.7. Market growth and outlook
4.8. Competition scoreboard
Chapter 5. Continuous Glucose Monitoring (CGM) Market Analysis, By Application
5.1. Key ideas
5.2. Market Size and Forecast, 2017 – 2030 (USD Million)
5.2.2. Transmitters and receivers
5.2.3. Integrated insulin pumps
Chapter 6. Continuous Glucose Monitoring (CGM) Market Analysis, By Demographics
6.1. Key ideas
6.2. Market Size and Forecast, 2017 – 2030 (USD Million)
6.2.1. Child population (
6.2.2. Adult population (> 14 years old)
Chapter 7. Continuous Glucose Monitoring (CGM) Market Analysis, By End User
7.1. Key ideas
7.2. Market Size and Forecast, 2017 – 2030 (USD Million)
7.2.1. Diagnostics / Clinics
7.2.3. Home care
Chapter 8. Continuous Glucose Monitoring (CGM) Market Analysis, By Region
8.1. Key ideas
8.2. Market Size and Forecast, 2017 – 2030 (USD Million)
8.2.4. South Korea
8.2.5. Australia and New Zealand
8.2.8. Rest of Asia-Pacific
A. Menarini Diagnostics
Echo Therapeutics, Inc.
Johnson & johnson
Senseonics Holdings, Inc.
F. Hoffmann-La Roche Ltée.
For more information on this report visit https://www.researchandmarkets.com/r/mtd784